We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




The New Frontiers of Nanobiotechnology

By Biotechdaily staff writers
Posted on 12 Sep 2003
Nanotechnology and medical biotechnology are interacting to create a new discipline called nanobiotechnology, which offers many new possibilities in disease detection, drug delivery, and imaging. More...
According to a new report from Frost & Sullivan (London, UK), nano-enabled services could potentially represent up to US$180 billion annually in medicine and healthcare by 2015.

Nanostructured materials have been developed that can serve as templates for tissue replacement and enable better treatment of burns, while researchers are attempting to induce bone tissue growth through polymer templates. Developments in nanoencaspulation promise enhanced delivery and absorption of drugs, and carbon nanotubes are being contemplated as a system for delivery of gene therapy. Magnetic nanoparticles containing drugs could be delivered to specific parts of the body by means of a magnetic field.

Encouraging developments in microfluidics enable the modification of drug levels within the body in real-time, avoiding fluctuations in concentration. Nanosensors are being used to detect DNA sequences in the body, and implanted nanosensors could enable simpler and more-effective diagnosis. Noninvasive imaging technologies such as tensor magnetic resonance imaging are designed to allow doctors to better detect the development, degeneration, and disease of soft tissue. Quantum dots, which have the ability to bond chemically to biologic molecules and emit bright fluorescent light, could be effective in detecting early carcinoma.

"With a new generation of nanochips, we could obtain much more accurate medical diagnosis; quickly and efficiently screen the mind-boggling array of drug candidates, and perform targeted delivery of drugs and vaccines like never before,” said Girish Solank, an analyst with Frost and Sullivan.




Related Links:
Frost & Sullivan

New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Repetitive Pipette
VWR® Stepper Pro
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.